UNSPSC 51413107: Fasudil hydrochloride hydrate

This classification denotes a protein kinase inhibitor with the molecular formula 2C14H17N3O2S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LI4L0R5Y7T, chemically known as isoquinoline, 5-((hexahydro-1h-1,4-diazepin-1-yl)sulfonyl)-, hydrochloride, hydrate (2:2:1), but more generally known as fasudil hydrochloride hydrate, which bears US NIH Compound Identifier 11954307.

European Medicines Agency schedules fasudil hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07515MIG. Most nations, for tariff purposes, schedule fasudil hydrochloride hydrate under HS 29350090. SMILES: C1CC2CNCCC2C(C1)S(=O)(=O)N3CCCNCC3.C1CC2CNCCC2C(C1)S(=O)(=O)N3CCCNCC3.O.CL.CL.

UNSPSC 51413107 Fasudil hydrochloride hydrate is a Commodity code representing individual pharmaceutical active ingredients and formulations procured by state and local health authorities for emergency medical services, institutional healthcare, and pharmacy benefit programs. State and local governments buy specific branded or generic medications under this code when they solicit through emergency services agencies, health departments, cooperative purchasing alliances, and state pharmacy benefit programs. Issuing bodies include municipal fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing organizations. Recent solicitations show procurement of individual medication line items—vials, injections, and tablets in specified strengths and quantities—rather than consolidated pharmaceutical supply contracts, with vendors required to meet strict expiration-date and shelf-life standards, maintain product safety documentation, and arrange replacement of expired stock before contract end.

Activity under this code is concentrated in the South and Upper Midwest. The City of Tampa Fire Rescue posted an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications including 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a one-year contract term renewable for two additional one-year periods and an estimated value of $40,000, with award made to the lowest responsive, responsible bidder and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to provide products through three authorized wholesalers with a two-year contract term and effective date of July 1, 2026. Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs to inform future formal solicitation strategy, signaling emerging state interest in alternative pharmaceutical procurement models outside traditional pharmacy benefit manager and wholesaler channels.